Showing results (161-170 of 330) with videos related to
Sort By:
Pageof 33
Cancer Discovery|October 15, 2013
Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis ConsortiumMatthew J Ellis, Michael Gillette, Steven A Carr, et al.Cancer Research|October 16, 2003
Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression statusMatthew J Ellis, Andrew Coop, Baljit Singh, et al.Critical Care Medicine|February 21, 2015
Detailed characterization of a long-term rodent model of critical illness and recoveryNeil E Hill, Saima Saeed, Rahul Phadke, et al.Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 12, 2012
EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assaysCaroline J Chapman, Graham F Healey, Andrea Murray, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 18, 2020
ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT TrialsNicholas C Turner, Claire Swift, Lucy Kilburn, et al.Breast Cancer Research and Treatment|April 23, 2013
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancerCynthia X Ma, Vera J Suman, Matthew Goetz, et al.Breast Cancer Research and Treatment|July 4, 2021
A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapyMei-Yin C Polley, Maura N Dickler, Jason Sinnwell, et al.The Lancet. Oncology|November 19, 2013
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trialAman U Buzdar, Vera J Suman, Funda Meric-Bernstam, et al.Journal of the National Cancer Institute|September 25, 2008
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristicsMatthew J Ellis, Yu Tao, Jingqin Luo, et al.Breast Cancer Research : BCR|April 12, 2023
Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)Judith M Bliss, Holly Tovey, Abigail Evans, et al.Pageof 33